L26/P-391 fertility outcomes in leukemia survivors by treatment modality: a systematic review and meta-analysis
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.725 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von J. Altmann und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Study question What is the prevalence of infertility among patients following treatment for leukemia, stratified by treatment modality, sex, and leukemia subtype? Summary answer Infertility risk varies by treatment, 68% with HSCT versus 13% without HSCT, females show greater HSCT-related vulnerability, and risk also differs among leukemia subtypes. What is known already Leukemia represents the most common malignant disease in childhood and adolescence, accounting for almost one-third of all cancer diagnoses. Treatment usually requires urgent initiation and includes standard multiagent chemotherapy, but may escalate to high-intensity modalities such as hematopoietic stem cell transplantation (HSCT) with or without total body irradiation (TBI). Due to the often young age at diagnosis, time constraints, and an unpredictable disease course, fertility preservation (FP) is especially challenging. Therefore, knowledge of treatment-related fertility risk is of high clinical relevance. However, a comprehensive meta-analysis of the gonadotoxic risks of leukemia treatments has not yet been conducted. Study design, size, duration Within the framework of the FertiTOX project, we conducted a systematic review and meta-analysis evaluating fertility outcomes in patients with leukemia following different treatment modalities. Studies published in MEDLINE, Embase, and the Cochrane Library between 01/2000 and 06/2024 were screened, study quality was assessed using the Newcastle-Ottawa Scale. Meta-analyses were performed using random-effects models, as heterogeneity was anticipated. Sensitivity analyses were stratified by treatment type, sex, and leukemia subtype to identify populations at increased risk. Participants/materials, setting, methods Human studies published in English or German were included, reporting original data from randomized controlled trials (RCTs), observational studies, pre-post studies, or editorials. Infertility was defined as premature ovarian insufficiency or amenorrhea in females aged <40; inhibin B < 80 pg/mL and FSH >10 IU/L, azoospermia, or inability to conceive after >12 months in males; hypergonadotropic hypogonadism, FSH >25 IU/L, or hormone replacement therapy in both sexes. Of 4,864 studies screened, 42 were included. Main results and the role of chance Overall: Infertility affected 37% (95% CI 0.23–0.54) of female and male leukemia survivors, with substantial heterogeneity (I² up to 91%). Stratification by cancer treatment: Chemotherapy alone was associated with an infertility prevalence of 4% (0–48%), combined chemo-radiotherapy with 9% (1–52%). HSCT-treated survivors had the highest infertility rate (68% [51–81%]) compared with 13% after non-HSCT regimens (5–32%; p < 0.0001). Stratification by type of irradiation: Testicular irradiation conferred the highest risk, with 92% (59–99%) infertility. Total body irradiation (TBI) ≥10–12 Gy was associated with 66% (49–80%) infertility and was comparable between sexes. Stratification by sex: Analyses suggested greater vulnerability in males following chemotherapy-only regimens (non-HSCT: 18% in males vs. 6% in females), whereas infertility rates after HSCT were higher in females (males: 59% [28–85%]; females: 70% [52–83%]). Stratification by leukemia subtype: Infertility prevalence was 46% (26–67%) in acute lymphoblastic leukemia (ALL), 49% (25–74%) in acute myeloid leukemia (AML), and 68% (3–99%) in chronic myeloid leukemia (CML), reflecting differences in treatment intensity (p < 0.001). Limitations, reasons for caution The generalizability of our findings is limited by the heterogeneity of the available data, partly incomplete reporting of treatment details, and variability in follow-up assessments and timing. An additional limiting factor is variability in treatment protocols over time, as some included studies reflect anticancer treatment regimens administered several decades ago. Wider implications of the findings Our findings underscore the need for risk-stratified and repeated oncofertility counseling throughout the disease trajectory, especially in women, as fertility preservation options are limited. Given the unpredictability of the treatment course, sperm cryopreservation is recommended prior to treatment initiation. Ovarian tissue cryopreservation may be carefully considered immediately before HSCT. Trial registration number Yes
Zitieren
APA
Altmann, J., Einsiedel, N., Pape, J., Weidlinger, S., Karrer, T., Balcerek, M., & Wolff, M. V. (2026). L26/P-391 fertility outcomes in leukemia survivors by treatment modality: a systematic review and meta-analysis. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.725
Vancouver
Altmann J, Einsiedel N, Pape J, Weidlinger S, Karrer T, Balcerek M, et al. L26/P-391 fertility outcomes in leukemia survivors by treatment modality: a systematic review and meta-analysis. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.725
BibTeX
@article{Altmann2026,
author = {Altmann, J. and Einsiedel, N. and Pape, J. and Weidlinger, S. and Karrer, T. and Balcerek, M. and Wolff, M. Von},
title = {L26/P-391 fertility outcomes in leukemia survivors by treatment modality: a systematic review and meta-analysis},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.725}
}
EUVIMED